Tebentafusp and roginolisib for uveal melanoma

This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.

This study tests whether a low dose of a steroid called dexamethasone can help prevent a side effect (cytokine release syndrome) that often happens when you first receive the cancer drug tebentafusp. It is for people with advanced uveal melanoma who are starting tebentafusp as their first treatment.

This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.

This trial provides access to tebentafusp, a treatment for advanced melanoma of the eye that cannot be removed by surgery. It may help control the disease.

This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.

This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.